Skip to content

SAFECODE DRUG TECHNOLOGIES CORP.: 10-K filed 2012-03-29

What SAFECODE DRUG TECHNOLOGIES CORP. reported in its annual report filed 2012-03-29 (fiscal FY 2011): 16 published measures, 44 facts as tagged in accession 0001144204-12-017866.

This filing

Form
10-K (annual report)
Filed
2012-03-29
Fiscal period
fiscal FY 2011
Accession
0001144204-12-017866 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SAFECODE DRUG TECHNOLOGIES CORP. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-12-3120,000USD
At 2010-12-3120,000USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2011-12-3170,617USD
At 2010-12-3131,761USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-12-31-50,617USD
At 2010-12-31-11,761USD
At 2010-11-220USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-12-310USD
At 2010-12-310USD
At 2010-11-220USD
At 2009-12-310USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-41,856USD365
2010-11-23 to 2011-12-31-53,617USD404
2010-11-23 to 2010-12-31-11,761USD39

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-23,909USD365
2010-11-23 to 2011-12-31-31,136USD404
2010-11-23 to 2010-12-31-7,227USD39

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-01-01 to 2011-12-3123,909USD365
2010-11-23 to 2011-12-3131,136USD404
2010-11-23 to 2010-12-317,227USD39

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-01-01 to 2011-12-310USD365
2010-11-23 to 2011-12-310USD404
2010-11-23 to 2010-12-310USD39

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2011-01-01 to 2011-12-310USD365
2010-11-23 to 2011-12-310USD404
2010-11-23 to 2010-12-310USD39

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-41,856USD365
2010-11-23 to 2011-12-31-53,617USD404
2010-11-23 to 2010-12-31-11,761USD39

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-12-3120,000USD
At 2010-12-3120,000USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-12-3170,617USD
At 2010-12-3131,761USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-01-01 to 2011-12-3141,856USD365
2010-11-23 to 2011-12-3153,617USD404
2010-11-23 to 2010-12-3111,761USD39

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-12-3130,000,000shares
At 2010-12-3130,000,000shares

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2011-01-01 to 2011-12-310USD365
2010-11-23 to 2011-12-310USD404
2010-11-23 to 2010-12-310USD39

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2011-01-01 to 2011-12-313,000USD365
2010-11-23 to 2011-12-313,000USD404
2010-11-23 to 2010-12-310USD39

Inspect the source

Entity
SAFECODE DRUG TECHNOLOGIES CORP. / CIK 0001508470
Captured
SEC response SHA-256
61bc881108e934e0196e3fd64982b23681ee67e455686f3698d5fc3741b1aa7c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001508470.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))